CohBar Investor Relations Material
Latest events
M&A Announcement
CohBar
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from CohBar Inc
Access all reports
CohBar Inc. is a clinical-stage biotechnology company focused on developing therapeutics based on peptides derived from mitochondrial DNA. The company’s research centers on leveraging its proprietary mitochondrial peptide technology platform to address chronic and age-related diseases. CohBar’s pipeline targets conditions such as metabolic disorders, fibrotic diseases, cancer, and neurodegenerative diseases. The company is headquartered in Menlo Park, California, and its shares are listed on the NASDAQ Stock Exchange.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
CWBR
Country
🇺🇸 United States